Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to 16,505.66%.

  • Silence Therapeutics' EBITDA Margin fell 1450319.00% to 16,505.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 321.21%, marking a year-over-year increase of 11438.00%. This contributed to the annual value of 146.38% for FY2024, which is 5709.00% up from last year.
  • Per Silence Therapeutics' latest filing, its EBITDA Margin stood at 16,505.66% for Q3 2025, which was down 54.29% from 10,697.77% recorded in Q2 2025.
  • Over the past 5 years, Silence Therapeutics' EBITDA Margin peaked at 1.36% during Q1 2022, and registered a low of 20,006.34% during Q1 2025.
  • In the last 3 years, Silence Therapeutics' EBITDA Margin had a median value of 633.59% in 2023 and averaged 4,854.74%.
  • In the last 5 years, Silence Therapeutics' EBITDA Margin soared by 61,639bps in 2024 and then plummeted by 1,997,079bps in 2025.
  • Silence Therapeutics' EBITDA Margin (MRQ) stood at 329.91% in 2021, then skyrocketed by 30bps to 230.03% in 2022, then tumbled by 175bps to 633.59% in 2023, then skyrocketed by 97bps to 17.20% in 2024, then crashed by 95,873bps to 16,505.66% in 2025.
  • Its EBITDA Margin was 16,505.66% in Q3 2025, compared to 10,697.77% in Q2 2025 and 20,006.34% in Q1 2025.